tirzepatide cv outcomes trial CARDIOVASCULAR EFFICACY OF IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS Timeline of cardiovascular outcome trials – Lilly begins dosing in cardiovascular

Research shows that hyaluronic acid works through multiple mechanisms to support joint health

Retatrutide (Eli Lilly and Co.) Retatrutide is a novel triple-hormone receptor agonist that simultaneously activates the GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors

Enhances the effectiveness of treatments As a potent regenerative ingredient, PDRN works synergistically with other active compounds in hair growth treatments, enhancing overall efficacy and accelerating results

doi: 10.1016/j.heliyon.2021.e07064 22 XuegangNQiYKaijianHYuTPenghuiWYangZet al

Specifically, individuals lost 22.8 kilograms on tirzepatide compared to 15.0 kilograms on semaglutide (Source: SURMOUNT-5 Trial, Wharton et al., NEJM 2025)